Dendreon (OTCMKTS:DNDNQ) versus iBio (NASDAQ:IBIO) Head-To-Head Analysis

Dendreon (OTCMKTS:DNDNQ) and iBio (NASDAQ:IBIO) are both manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Dendreon and iBio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dendreon	N/A	N/A	N/A	N/A	N/A
iBio	$400,000.00	189.97	-$18.38 million	($1.00)	-2.20

Dendreon has higher earnings, but lower revenue than iBio.

Analyst Recommendations

This is a breakdown of recent recommendations for Dendreon and iBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dendreon	0	0	0	0	0.00
iBio	1	0	2	3	3.17

iBio has a consensus price target of $4.75, suggesting a potential upside of 115.91%. Given iBio’s stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Dendreon.

Insider & Institutional Ownership

7.9% of iBio shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dendreon and iBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dendreon	N/A	N/A	N/A
iBio	N/A	-71.26%	-57.92%

Summary

iBio beats Dendreon on 7 of the 9 factors compared between the two stocks.

About Dendreon

Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.